Butterfly Network Faces Stock Decline Amid Executive Share Sale
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Source: seekingalpha
Butterfly Network Inc. shares fell 5.16% as the stock crossed below its 5-day SMA, reflecting investor concerns.
The decline follows the disclosure of a significant share sale by Chief Business Officer Steve Cashman, who sold 399,461 shares for approximately $1.89 million, representing 19.68% of his holdings. This transaction, occurring at a price of $4.74 per share, raises questions about the company's future prospects despite recent revenue growth of 19% in 2025 and 25% in Q1 2026. The market is reacting to the potential risks associated with the licensing agreement with Midjourney, which could impact future growth stability.
Investors are advised to remain cautious as the market digests the implications of this executive sell-off, particularly in light of the concentration risk tied to the licensing deal and the overall market downturn.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.230
Low
4.00
Averages
4.25
High
4.50
Current: 8.230
Low
4.00
Averages
4.25
High
4.50
About BFLY
Butterfly Network, Inc. is a digital health business offering care through a combination of portable, semiconductor-based ultrasound technology, intuitive software, services, and educational offerings. Its ultrasound devices can perform whole-body imaging with a single handheld probe. Its Ultrasound-on-Chip makes ultrasound accessible outside of healthcare institutions, while its software is intended to make the product fully integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and any hospital computer system. It markets and sells the Butterfly system, which includes probes, related accessories, and software subscriptions, to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and its e-commerce channel. It licenses its Ultrasound-on-Chip semiconductor platform for co-development of novel technologies through its Embedded program. Its products consist of iQ3, iQ+, iQ+ Bladder, and Compass AI software.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chewy's Stock Performance Declines, Investors Find It Hard to Hold
- Chewy's Stock Performance: Chewy's year-to-date stock performance has been disappointing, with investors stating that it is 'too hard to own,' reflecting concerns about its future profitability and potentially leading to decreased investor confidence.
- Butterfly Network's Outlook: Despite not being profitable, Butterfly Network is viewed as a promising investment at $8 per share, indicating market expectations for future growth that may attract risk-seeking investors.
- Nextpower's Investment Review: Nextpower's founder, Dan Shugar, is referred to as a 'miracle worker,' and while investors acknowledge their mistake in selling early, the positive outlook for the company may draw more investor interest.
- Preformed Line Products' Prospects: Preformed Line Products is compared to a 'mini Quanta Services,' with optimistic market sentiment about its growth potential, and if communities cease to reject data center constructions, its stock price could rise further.
See More
Butterfly Network Executive Sells Nearly 400K Shares
- Executive Share Sale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the sale of 399,461 shares on June 5 and 8, 2026, totaling approximately $1.89 million, representing 19.68% of his direct holdings, indicating a cautious outlook on the company's future.
- Transaction Price Analysis: The weighted average sale price was $4.74 per share, while the market close on June 8, 2026, was $4.78, suggesting Cashman sold at a relatively high point, potentially reflecting concerns about future stock price movements.
- Revenue Growth Overview: Despite Butterfly Network achieving a 19% revenue growth in 2025 and 25% in Q1 2026, these figures do not fully account for the stock's volatility, highlighting market uncertainty regarding the company's future trajectory.
- Impact of Licensing Agreement: The licensing deal with Midjourney provides Butterfly with a minimum annual fee of $10 million and milestone payments up to $9 million, which, while significant, introduces customer concentration risk that could affect future growth stability.
See More
Butterfly Network Executive Sells 399,461 Shares in Major Transaction
- Executive Stock Sale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of Common Stock on June 5 and 8 for approximately $1.89 million, indicating a potential lack of confidence in the company's future prospects.
- Largest Single Transaction: This sale marks Cashman's largest open-market transaction to date, surpassing his previous maximum of 250,000 shares sold on February 26, 2026, suggesting that his decisions may be influenced by market volatility.
- Change in Ownership Proportion: The sale represented 19.68% of his direct holdings, leaving him with 1,630,407 shares post-transaction, which indicates his continued significant position in the company but raises questions about his future intentions regarding ownership.
- Market Reaction and Risks: Despite Butterfly Network's revenue growth of 19% in 2025 and 25% in Q1 2026, there are doubts about whether the stock's rapid rise reflects genuine business improvement, particularly given the concentration risk associated with its licensing deal with Midjourney, which could impact future growth potential.
See More
Butterfly Network Executive Sells 399K Shares
- Executive Sell-off Scale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of common stock on June 5 and 8, 2026, totaling approximately $1.89 million, marking his largest single open-market sale to date, exceeding his previous maximum of 250,000 shares, indicating a cautious outlook on the company's future.
- Shareholding Proportion Change: This sale represented 19.68% of Cashman's direct holdings, leaving him with 1,630,407 shares post-transaction, suggesting that despite the sell-off, he maintains a significant stake in the company, which could influence market confidence.
- Market Reaction Analysis: Although Butterfly Network's revenue grew by 19% in 2025 and 25% in Q1 2026, the market's rapid price increase raises concerns, as a significant portion of future revenue is tied to a licensing deal with Midjourney, presenting a concentration risk for investors.
- Investor Strategy Recommendation: Analysts advise investors to exercise patience when considering Butterfly Network stock, especially given the stable performance of its core ultrasound business, as the sustainability of recent licensing revenue remains to be seen amid the stock's recent price surge.
See More
Butterfly Launches Handheld Ultrasound Devices in Brazil
- Market Expansion: Butterfly Network's launch of its handheld ultrasound devices iQ+ and iQ3 in Brazil marks a significant step in its international growth strategy, as Brazil represents the largest medical device market in Latin America with substantial market potential.
- Technological Advantage: By successfully meeting Brazil's regulatory and certification requirements, Butterfly demonstrates the strength of its ultrasound technology, providing reliable solutions for clinicians in high-standard markets, thereby enhancing its competitive edge.
- Improved Accessibility: The introduction of these devices not only increases diagnostic capacity in high-volume hospitals and emergency settings but also improves healthcare access in underserved rural communities, enabling more patients to receive timely medical imaging.
- Global Footprint Expansion: The commercial launch in Brazil further extends Butterfly's global market presence, supporting its mission to increase access to its technology in key international markets and advance the democratization of medical imaging.
See More
Jim Cramer Endorses Medline as Best IPO of the Year
- IPO Outlook: Jim Cramer identifies Medline as the best IPO of the year, indicating strong market confidence in its future performance, which may attract more investor interest.
- Investment Recommendation: Cramer explicitly endorses Medline on his show, emphasizing its investment value, which could drive stock price increases and bolster market confidence.
- Positive Market Reaction: Medline's performance gains recognition from Cramer, potentially prompting more analysts to focus on it and provide favorable evaluations, thereby enhancing its market position.
- Risk and Opportunity: While Cramer mentions Nuscale Power as speculative, his positive view on Medline highlights its relative safety in the current market environment, appealing to risk-averse investors.
See More
Chewy's Stock Performance Declines, Investors Find It Hard to Hold
- Chewy's Stock Performance: Chewy's year-to-date stock performance has been disappointing, with investors stating that it is 'too hard to own,' reflecting concerns about its future profitability and potentially leading to decreased investor confidence.
- Butterfly Network's Outlook: Despite not being profitable, Butterfly Network is viewed as a promising investment at $8 per share, indicating market expectations for future growth that may attract risk-seeking investors.
- Nextpower's Investment Review: Nextpower's founder, Dan Shugar, is referred to as a 'miracle worker,' and while investors acknowledge their mistake in selling early, the positive outlook for the company may draw more investor interest.
- Preformed Line Products' Prospects: Preformed Line Products is compared to a 'mini Quanta Services,' with optimistic market sentiment about its growth potential, and if communities cease to reject data center constructions, its stock price could rise further.
See More
Butterfly Network Executive Sells Nearly 400K Shares
- Executive Share Sale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the sale of 399,461 shares on June 5 and 8, 2026, totaling approximately $1.89 million, representing 19.68% of his direct holdings, indicating a cautious outlook on the company's future.
- Transaction Price Analysis: The weighted average sale price was $4.74 per share, while the market close on June 8, 2026, was $4.78, suggesting Cashman sold at a relatively high point, potentially reflecting concerns about future stock price movements.
- Revenue Growth Overview: Despite Butterfly Network achieving a 19% revenue growth in 2025 and 25% in Q1 2026, these figures do not fully account for the stock's volatility, highlighting market uncertainty regarding the company's future trajectory.
- Impact of Licensing Agreement: The licensing deal with Midjourney provides Butterfly with a minimum annual fee of $10 million and milestone payments up to $9 million, which, while significant, introduces customer concentration risk that could affect future growth stability.
See More
Butterfly Network Executive Sells 399,461 Shares in Major Transaction
- Executive Stock Sale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of Common Stock on June 5 and 8 for approximately $1.89 million, indicating a potential lack of confidence in the company's future prospects.
- Largest Single Transaction: This sale marks Cashman's largest open-market transaction to date, surpassing his previous maximum of 250,000 shares sold on February 26, 2026, suggesting that his decisions may be influenced by market volatility.
- Change in Ownership Proportion: The sale represented 19.68% of his direct holdings, leaving him with 1,630,407 shares post-transaction, which indicates his continued significant position in the company but raises questions about his future intentions regarding ownership.
- Market Reaction and Risks: Despite Butterfly Network's revenue growth of 19% in 2025 and 25% in Q1 2026, there are doubts about whether the stock's rapid rise reflects genuine business improvement, particularly given the concentration risk associated with its licensing deal with Midjourney, which could impact future growth potential.
See More
Butterfly Network Executive Sells 399K Shares
- Executive Sell-off Scale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of common stock on June 5 and 8, 2026, totaling approximately $1.89 million, marking his largest single open-market sale to date, exceeding his previous maximum of 250,000 shares, indicating a cautious outlook on the company's future.
- Shareholding Proportion Change: This sale represented 19.68% of Cashman's direct holdings, leaving him with 1,630,407 shares post-transaction, suggesting that despite the sell-off, he maintains a significant stake in the company, which could influence market confidence.
- Market Reaction Analysis: Although Butterfly Network's revenue grew by 19% in 2025 and 25% in Q1 2026, the market's rapid price increase raises concerns, as a significant portion of future revenue is tied to a licensing deal with Midjourney, presenting a concentration risk for investors.
- Investor Strategy Recommendation: Analysts advise investors to exercise patience when considering Butterfly Network stock, especially given the stable performance of its core ultrasound business, as the sustainability of recent licensing revenue remains to be seen amid the stock's recent price surge.
See More
Butterfly Launches Handheld Ultrasound Devices in Brazil
- Market Expansion: Butterfly Network's launch of its handheld ultrasound devices iQ+ and iQ3 in Brazil marks a significant step in its international growth strategy, as Brazil represents the largest medical device market in Latin America with substantial market potential.
- Technological Advantage: By successfully meeting Brazil's regulatory and certification requirements, Butterfly demonstrates the strength of its ultrasound technology, providing reliable solutions for clinicians in high-standard markets, thereby enhancing its competitive edge.
- Improved Accessibility: The introduction of these devices not only increases diagnostic capacity in high-volume hospitals and emergency settings but also improves healthcare access in underserved rural communities, enabling more patients to receive timely medical imaging.
- Global Footprint Expansion: The commercial launch in Brazil further extends Butterfly's global market presence, supporting its mission to increase access to its technology in key international markets and advance the democratization of medical imaging.
See More
Jim Cramer Endorses Medline as Best IPO of the Year
- IPO Outlook: Jim Cramer identifies Medline as the best IPO of the year, indicating strong market confidence in its future performance, which may attract more investor interest.
- Investment Recommendation: Cramer explicitly endorses Medline on his show, emphasizing its investment value, which could drive stock price increases and bolster market confidence.
- Positive Market Reaction: Medline's performance gains recognition from Cramer, potentially prompting more analysts to focus on it and provide favorable evaluations, thereby enhancing its market position.
- Risk and Opportunity: While Cramer mentions Nuscale Power as speculative, his positive view on Medline highlights its relative safety in the current market environment, appealing to risk-averse investors.
See More
